SCHEMBL3072274

SCHEMBL3072274

CC(=O)NCCc1ccc(F)cc1OCCOC1CN(C(=O)O)CCC1c1ccc(O)cc1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
MTNR1A P48039 3/20 0.33
MTNR1B P49286 3/20 0.33
RBP4 P02753 1/20 0.33
NOTUM Q6P988 1/20 0.33
F10 P00742 1/20 0.33
GAA P10253 1/20 0.33
NPC1 O15118 1/20 0.33
APOBEC3A P31941 1/20 0.33
RAB9A P51151 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33
ADRB1 P08588 1/20 0.32
ADRB3 P13945 1/20 0.32
FOLH1 Q04609 1/20 0.32
REN P00797 1/20 0.32
KDM4E B2RXH2 1/20 0.31
F13A1 P00488 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3414880 0.91 MAOB (0.38) MTNR1AMTNR1BGAAREN
SCHEMBL3078010 0.91 MTNR1A (0.38) MTNR1AMTNR1BGAANPC1APOBEC3A
SCHEMBL3081602 0.90 MAPT (0.40) CNR1CNR2
SCHEMBL3059850 0.88 MTNR1A (0.42) MTNR1AMTNR1BGAAREN
SCHEMBL3071552 0.87 MTNR1A (0.38) MTNR1AMTNR1BGAANPC1APOBEC3A
SCHEMBL3072453 0.86 REN (0.49) MTNR1AMTNR1BNPC1APOBEC3ARAB9A
SCHEMBL3067279 0.83 YAP1 (0.42)
SCHEMBL3070956 0.82 MTNR1B (0.44) MTNR1AMTNR1BNPC1APOBEC3ARAB9A
SCHEMBL3078046 0.81 REN (0.49) MTNR1AMTNR1BREN
SCHEMBL3072492 0.80 REN (0.43) GAANPC1APOBEC3ARAB9AAPOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842688-B2 Organic compounds NOVARTIS PHARMA AG (CH) 2010-11-30 US disclosed
US-7790715-B2 Organic compounds NOVARTIS AG (CH) 2010-09-07 US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 EP disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012055-A1 Organic compounds REN, ACE, ACE2 CNR1 1539/4885CNR2 1456/4885MTNR1A 2695/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 CNR1 1539/4885CNR2 1456/4885MTNR1A 2695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.